Medtronic plc (ETR:2M6)
76.99
+0.49 (0.64%)
Jul 18, 2025, 5:35 PM CET
Revenue by Product
Fiscal year is May - April.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Apr '25 Apr 25, 2025 | Apr '24 Apr 26, 2024 | Apr '23 Apr 28, 2023 | Apr '22 Apr 29, 2022 | Apr '21 Apr 30, 2021 | 2013 - 2020 |
Cardiac Rhythm & Heart Failure | 6.39B | Log In | Log In | Log In | Log In | Upgrade |
Cardiac Rhythm & Heart Failure Growth | 6.61% | Log In | Log In | Log In | Log In | Upgrade |
Diabetes | 2.76B | Log In | Log In | Log In | Log In | Upgrade |
Diabetes Growth | 10.73% | Log In | Log In | Log In | Log In | Upgrade |
Medical Surgical | - | Log In | Log In | Log In | Log In | Upgrade |
Medical Surgical Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Structural Heart & Aortic | 3.55B | Log In | Log In | Log In | Log In | Upgrade |
Structural Heart & Aortic Growth | 5.84% | Log In | Log In | Log In | Log In | Upgrade |
Coronary & Peripheral Vascular | 2.54B | Log In | Log In | Log In | Log In | Upgrade |
Coronary & Peripheral Vascular Growth | 2.34% | Log In | Log In | Log In | Log In | Upgrade |
Cranial & Spinal Technologies | 4.97B | Log In | Log In | Log In | Log In | Upgrade |
Cranial & Spinal Technologies Growth | 4.58% | Log In | Log In | Log In | Log In | Upgrade |
Specialty Therapies | 2.94B | Log In | Log In | Log In | Log In | Upgrade |
Specialty Therapies Growth | 1.27% | Log In | Log In | Log In | Log In | Upgrade |
Neuromodulation | 1.93B | Log In | Log In | Log In | Log In | Upgrade |
Neuromodulation Growth | 10.71% | Log In | Log In | Log In | Log In | Upgrade |
Surgical & Endoscopy | 6.50B | Log In | Log In | Log In | Log In | Upgrade |
Surgical & Endoscopy Growth | -0.15% | Log In | Log In | Log In | Log In | Upgrade |
Acute Care & Monitoring | 1.91B | Log In | Log In | Log In | Log In | Upgrade |
Acute Care & Monitoring Growth | 0.05% | Log In | Log In | Log In | Log In | Upgrade |
Other Segment | 137.00M | Log In | Log In | Log In | Log In | Upgrade |
Other Segment Growth | -37.56% | Log In | Log In | Log In | Log In | Upgrade |
Other | -89.00M | Log In | Log In | Log In | Log In | Upgrade |
Other | -89.00M | Log In | Log In | Log In | Log In | Upgrade |
EBIT by Product
Fiscal year is May - April.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Apr '25 Apr 25, 2025 | Apr '24 Apr 26, 2024 | Apr '23 Apr 28, 2023 | Apr '22 Apr 29, 2022 | Apr '21 Apr 30, 2021 | 2013 - 2020 |
Other | -6.11B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 8.25% | Log In | Log In | Log In | Log In | Upgrade |
Cardiovascular Operating Profit | 4.80B | Log In | Log In | Log In | Log In | Upgrade |
Cardiovascular Operating Profit Growth | 7.31% | Log In | Log In | Log In | Log In | Upgrade |
Neuroscience Operating Profit | 4.18B | Log In | Log In | Log In | Log In | Upgrade |
Neuroscience Operating Profit Growth | 6.17% | Log In | Log In | Log In | Log In | Upgrade |
Medical Surgical Operating Profit | 3.04B | Log In | Log In | Log In | Log In | Upgrade |
Medical Surgical Operating Profit Growth | -4.43% | Log In | Log In | Log In | Log In | Upgrade |
Diabetes Operating Profit | 491.00M | Log In | Log In | Log In | Log In | Upgrade |
Diabetes Operating Profit Growth | 24.62% | Log In | Log In | Log In | Log In | Upgrade |
Other | -6.11B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 8.25% | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is May - April.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Apr '25 Apr 25, 2025 | Apr '24 Apr 26, 2024 | Apr '23 Apr 28, 2023 | Apr '22 Apr 29, 2022 | Apr '21 Apr 30, 2021 | 2013 - 2020 |
U.S. | 17.17B | Log In | Log In | Log In | Log In | Upgrade |
U.S. Growth | 3.67% | Log In | Log In | Log In | Log In | Upgrade |
Non-U.S. Developed Markets | 10.20B | Log In | Log In | Log In | Log In | Upgrade |
Non-U.S. Developed Markets Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Emerging Markets | 6.20B | Log In | Log In | Log In | Log In | Upgrade |
Emerging Markets Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other
Fiscal year is May - April.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Apr '25 Apr 25, 2025 | Apr '24 Apr 26, 2024 | Apr '23 Apr 28, 2023 | Apr '22 Apr 29, 2022 | Apr '21 Apr 30, 2021 | 2013 - 2020 |
Total Organic Revenue Growth | 4.90% | Log In | Log In | Log In | Log In | Upgrade |
Cardiovascular Organic Revenue Growth | 6.30% | Log In | Log In | Log In | Log In | Upgrade |
Neuroscience Organic Revenue Growth | 5.20% | Log In | Log In | Log In | Log In | Upgrade |
Medical Surgical Organic Revenue Growth | 0.80% | Log In | Log In | Log In | Log In | Upgrade |
Diabetes Organic Revenue Growth | 11.50% | Log In | Log In | Log In | Log In | Upgrade |